Official Title
Study of INFLAmmasome NLRP3 and PLAtelets Functions During Severe COVID-19 Infection
Brief Summary

COVID-19 pandemic is a severe viral sepsis characterized by the occurrence of Acute respiratory distress syndrome (ARDS) whose pathophysiology is little described

Detailed Description

The new Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic started on
December 2019 in China and spreaded in worldwide. The Coronavirus disease 2019 (COVID-19) is
responsible of case of severe pneumonia whose the major risk is the development to ARDS.
Concerning the pathophysiology, there appear to be hemostasis abnormalities including
thrombocytopenia and coagulopathy. In recent studies, this thrombocytopenia is described as a
risk factor to develop severe COVID-19 infection. Sepsis is associated with a major systemic
inflammatory response with an increased production of pro-inflammatory cytokines. Since their
discovery, inflammasomes have an important role during inflammatory response following an
aggression. There are intracytoplasmic multiprotein complex activated by cellular stress or
infections and is responsible for the release of pro-inflammatory cytokines, including IL-1β.
Most studies have analysed inflammasomes in nucleated cells, nevertheless, little is known
about inflammasomes in platelets.

Thus, the present work aims to study the activation of the platelet NLRP3 inflammasome and
the platelet functions and coagulation during a SARS-CoV-2 viral pneumonia according to
different levels of severity

Unknown status
COVID-19

Biological: Blood samples

Blood samples will be collected in peripheral blood at the admission in intensive care unit or in standard care unit to compare platelet inflammasome NLRP3 and others markers

Eligibility Criteria

Inclusion Criteria:

- Patients suffering from COVID-19, hospitalized in intensive care unit and in standard
care unit.

Exclusion Criteria:

- Patients suffering from malignant blood disease, cryopyrinopathy, sickle cell disease,
rheumatoid arthritis and Crohn's disease

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

CHU Toulouse
Toulouse, France

Investigator: Fanny BOUNES
bounes.f@chu-toulouse.fr

Investigator: Fanny BOUNES

Contacts

Fanny BOUNES
05 61 32 27 99
bounes.f@chu-toulouse.fr

Fanny BOUNES, Principal Investigator
University Hospital, Toulouse

University Hospital, Toulouse
NCT Number
Keywords
Covid-19
NLRP3 inflammasome
Platelets functions
coagulopathy
Acute Respiratory Distress Syndrome
MeSH Terms
COVID-19